Ksenia Titorenko

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

J. Radich, F. Giles, G. Saglio, 2021, Leukemia.

A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.

K. Yoo, H. Shimada, C. Zwaan, 2021, Blood advances.

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

I. Flinn, R. Larson, R. Clark, 2021, Leukemia.

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom

J. Radich, F. Giles, G. Saglio, 2020 .

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

I. Flinn, R. Larson, R. Clark, 2019, Blood.